Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study
Novartis AG (NYSE:NVS) is one of the best pharma stocks to invest in now. Novartis AG (NYSE:NVS) announced on…
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
– Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA…
Novartis reports final data of ALIGN trial in IgAN
Novartis has announced final data from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slowed kidney function…